Compare OII & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OII | ADPT |
|---|---|---|
| Founded | 1964 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | N/A | 2019 |
| Metric | OII | ADPT |
|---|---|---|
| Price | $24.68 | $18.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $25.00 | $16.60 |
| AVG Volume (30 Days) | 744.0K | ★ 2.4M |
| Earning Date | 10-22-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.60 | N/A |
| EPS | ★ 2.29 | N/A |
| Revenue | ★ $2,829,032,000.00 | $252,754,000.00 |
| Revenue This Year | $5.78 | $36.43 |
| Revenue Next Year | $1.81 | $12.31 |
| P/E Ratio | $10.78 | ★ N/A |
| Revenue Growth | 8.71 | ★ 42.57 |
| 52 Week Low | $15.46 | $5.81 |
| 52 Week High | $30.98 | $20.76 |
| Indicator | OII | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 59.67 | 61.44 |
| Support Level | $22.77 | $13.28 |
| Resistance Level | $24.95 | $20.76 |
| Average True Range (ATR) | 0.74 | 1.08 |
| MACD | 0.14 | 0.45 |
| Stochastic Oscillator | 85.07 | 73.83 |
Oceaneering International Inc is a provider of engineered services and products and robotic solutions to the offshore energy, defense, aerospace, manufacturing, and entertainment industries. A majority of its products are produced for the offshore oil and gas market. The company's business segments are Integrity Management and Digital Solutions, Subsea Robotics, Manufactured Products, Offshore Projects Group, and Aerospace and Defense Technologies. Maximum revenue is generated from its Subsea Robotics segment, which provides remotely operated vehicles (ROVs) for drill support and vessel-based services, underwater surveys, tooling, and other activities. Geographically, the company derives its key revenue from the United States, followed by Africa, Norway, Brazil, and other regions.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).